Drug intelligence / Profile preview

ACK-122

Development stage: Unknown
Lead developer: Aquavit Pharmaceuticals
Modality: Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
Administration: Topical, Intradermal

Overview

**ACK-122** is an Aquavit Pharmaceuticals development-stage combination product listed for **actinic keratosis**. Publicly available sponsor material identifies the program code, product classification, and intended dermatologic indication, but does not disclose its active ingredient composition, dosage form, route of administration, molecular targets, mechanism of action, or clinical development phase.

Beyond the preview

Go deeper on ACK-122.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACK-122.

Explore the full profile